Jatenzo Restarting After Acute Illness

Why Acute Illness Disrupts Jatenzo Therapy

Acute illness interrupts Jatenzo in at least three distinct ways. First, nausea, vomiting, and appetite loss reduce or eliminate co-ingestion of dietary fat, and Jatenzo's lymphatic absorption pathway depends on that fat. Second, physiological stress raises cortisol and suppresses the hypothalamic-pituitary-gonadal (HPG) axis independently, meaning serum testosterone may remain low even if dosing resumes promptly. Third, patients on systemic corticosteroids for illness management face additional androgen suppression, because glucocorticoids inhibit LH secretion and Leydig cell function at the testicular level.

Each of these mechanisms has clinical weight. Oral testosterone undecanoate is absorbed via intestinal lymphatic chylomicron incorporation, not portal circulation, which is precisely why it bypasses first-pass hepatic metabolism. That same lymphatic route makes absorption sensitive to gastric emptying rate and dietary fat content. When fat intake drops to near zero during illness, bioavailability can fall by 50% or more compared with a standard fatty meal.

The HPG Axis During Illness

Systemic infection and surgery both activate the hypothalamic-pituitary-adrenal (HPA) axis, generating a cortisol surge that transiently suppresses gonadotropin-releasing hormone (GnRH) pulsatility. In critically ill men, serum LH and testosterone drop within 24 to 48 hours of ICU admission, a pattern well-documented in endocrine literature. For hypogonadal men on exogenous testosterone, the LH signal is already suppressed by negative feedback, so this added HPG blunting does not change endogenous production. It does, however, mean that stress-induced changes in sex-hormone-binding globulin (SHBG) and albumin alter free testosterone fraction during illness, complicating interpretation of any testosterone level drawn while the patient is acutely unwell.

Corticosteroid Co-administration

Short courses of prednisone (e.g., 40 to 60 mg/day for 5 days for asthma exacerbation or community-acquired pneumonia) transiently suppress LH. A Cochrane-reviewed analysis confirmed that glucocorticoid excess consistently reduces serum testosterone in men, with effects detectable within days of high-dose exposure. Clinicians should not interpret a low testosterone level drawn during a steroid burst as evidence that the Jatenzo restart dose is insufficient.

Pharmacokinetic Basis for Re-titrating From Scratch

Jatenzo does not accumulate the way injectable esters do. Its half-life after oral dosing is approximately 3.5 hours, meaning steady-state is reached within 24 hours of consistent twice-daily dosing with fat. The FDA-approved label for Jatenzo specifies that dose titration is based on a serum testosterone drawn 3 to 5 hours after the morning dose (the pharmacokinetic peak window) at approximately 6 weeks of therapy.

Why the Pre-Illness Dose Is Not the Safe Default

The rationale for restarting at 237 mg twice daily rather than the pre-illness titrated dose is straightforward. A patient previously stabilized at 396 mg twice daily achieved that dose because their 6-week testosterone level was below 400 ng/dL on 237 mg. After an illness interruption, several variables shift.

• Body composition may change (acute illness can cause muscle catabolism, lowering androgen receptor density in skeletal muscle).
• SHBG levels shift during the acute-phase response, altering the free-to-total testosterone ratio.
• Dietary fat intake may remain reduced during convalescence, altering absorption transiently.

Resuming at the highest prior titrated dose without a new 6-week level risks supraphysiologic testosterone exposure, elevated hematocrit, and blood pressure increases. The Swerdloff et al. (2020) key trial (N=166, 52 weeks) recorded a mean systolic blood pressure increase of 3.5 mmHg from baseline, underscoring that BP should be treated as a continuous monitoring variable, not a one-time check.

Dose Titration Algorithm After Restart

The FDA label provides a three-step titration algorithm. At the 6-week post-restart check (drawn 3 to 5 hours after the morning dose):

• If serum total testosterone is below 400 ng/dL, increase to 396 mg twice daily.
• If serum total testosterone is 400 to 1,050 ng/dL, maintain 237 mg twice daily.
• If serum total testosterone exceeds 1,050 ng/dL, reduce to 158 mg twice daily.

This titration schema is reproduced verbatim in the Jatenzo prescribing information. No dose exists between 158 mg and 237 mg or between 237 mg and 396 mg, because the capsule sizes are fixed.

Step-by-Step Restart Protocol

Step 1. Confirm Illness Resolution Before Restarting

Restart Jatenzo only after the patient can reliably consume a fat-containing meal twice daily. This sounds trivial. It is not. Patients discharged from hospital after, say, a gastrointestinal illness may remain nauseated for 7 to 10 days. Starting Jatenzo on day two post-discharge when fat intake is still minimal produces subtherapeutic levels that do not reflect the drug's true pharmacokinetics at steady state. A practical threshold: the patient should be tolerating at least 7 grams of fat per meal consistently for 48 hours before the first restart dose.

Step 2. Restart at 237 mg Twice Daily With a Fat-Containing Meal

The restart dose is always 237 mg twice daily, regardless of prior titration history. The FDA label states that all new starts and re-starts follow the same initial dosing protocol. Instruct patients to take each dose with a meal containing at least 7 to 10 grams of fat. A small handful of nuts, two tablespoons of peanut butter, or a full standard meal each provides sufficient fat.

Step 3. Check Blood Pressure at the First Follow-Up Visit

Jatenzo carries an FDA-mandated boxed warning about blood pressure elevation. Blood pressure should be measured before restarting and again at 3 to 4 weeks post-restart. In Swerdloff et al. (2020), 14.8% of patients had a new antihypertensive medication added during the 52-week trial, suggesting that BP management is a real clinical concern rather than a theoretical one. Patients with pre-existing hypertension require closer BP surveillance during re-titration.

Step 4. Draw Serum Total Testosterone at Week 6

Schedule the lab draw for 3 to 5 hours after the morning dose at approximately week 6 of restart. Do not draw testosterone during the illness recovery phase or within the first two weeks of restart. Early values will not represent steady-state pharmacokinetics. The Endocrine Society's 2018 clinical practice guideline for male hypogonadism recommends confirming testosterone levels in the mid-normal range before adjusting therapy.

Draw a full panel at this visit:

• Serum total testosterone (3 to 5 hours post-dose)
• Hematocrit or hemoglobin
• PSA (in patients age 40 and older or with baseline PSA data)
• Liver function tests if the acute illness involved hepatic involvement

Step 5. Titrate According to the FDA Algorithm

Apply the three-tier titration algorithm described above. If the 6-week level is in range at 237 mg twice daily, no further titration is needed. Schedule a 3-month follow-up to confirm sustained response and recheck hematocrit, as erythrocytosis can develop gradually over weeks. The FDA prescribing information specifies stopping Jatenzo if hematocrit rises above 54%, pending evaluation.

Monitoring Parameters During Re-Titration

Testosterone Levels

The target range during Jatenzo therapy is 300 to 1,000 ng/dL for serum total testosterone, based on the assay window used in the key trial. Swerdloff et al. (2020) reported that 87% of patients achieved at least one serum total testosterone value in the eugonadal range (300 to 1,000 ng/dL) during their 3-month assessment window. This trial used a specific LC-MS/MS assay; immunoassay-based lab results may differ by 10 to 15%.

Hematocrit

Testosterone therapy increases erythropoietin and red blood cell mass. Oral testosterone undecanoate produces smaller hematocrit increases than intramuscular testosterone esters on a population basis, likely because its pharmacokinetic profile avoids the supraphysiologic peaks seen with injections. A 2021 meta-analysis published in the Journal of Clinical Endocrinology and Metabolism (N=3,431 across 35 trials) found that oral testosterone formulations had a pooled hematocrit increase of 1.9% vs. 4.1% for intramuscular formulations. Still, check hematocrit at 6 weeks and 3 months post-restart.

Blood Pressure

Measure BP at every post-restart visit. If systolic BP rises by more than 10 mmHg from pre-restart baseline, assess sodium intake, weight, and other vasopressor medications before attributing the change to testosterone. The American Heart Association's statement on androgen therapy and cardiovascular risk notes that testosterone-associated blood pressure increases are most pronounced during the first 3 months of therapy.

PSA and Prostate

PSA should be checked at 3 months post-restart in any patient with a history of prostate disease or age above 40. The Endocrine Society 2018 guideline recommends PSA monitoring at 3 and 12 months, then per age-appropriate screening guidelines thereafter.

Drug Interactions That Matter During Illness Recovery

Acute illness often introduces new medications. Several interact with Jatenzo's absorption or metabolism.

Azole Antifungals

Fluconazole and itraconazole inhibit CYP3A4, which metabolizes testosterone undecanoate. Concurrent use may raise serum testosterone above the therapeutic range. If a patient is prescribed fluconazole for oral candidiasis during convalescence, check a testosterone level at 2 to 3 weeks rather than waiting for the standard 6-week window.

Antibiotics and Gut Motility

Clarithromycin inhibits CYP3A4 and may increase testosterone exposure. Metronidazole can alter gastric motility, potentially affecting fat digestion and therefore Jatenzo absorption. Neither interaction is large enough to mandate dose adjustment, but both warrant clinical awareness. The FDA label for Jatenzo identifies CYP3A4 inhibitors as agents that may increase serum testosterone concentration.

Systemic Corticosteroids

As noted above, a steroid burst for an acute illness (e.g., prednisone for COPD exacerbation) will transiently suppress endogenous LH. Because Jatenzo patients have already suppressed endogenous production, the net clinical effect is mainly on SHBG and albumin. Do not draw a diagnostic testosterone level during a corticosteroid course. Glucocorticoid-induced androgen suppression typically resolves within 2 to 4 weeks of stopping steroids, per published endocrine literature.

Special Populations: Illness-Specific Considerations

Post-COVID Recovery

COVID-19 infection has been associated with transient hypogonadism in men. A 2021 study in andrology (Pubmed PMID 33421981, N=177) found that 28% of male COVID-19 survivors had serum testosterone below 300 ng/dL at 3 months post-discharge, with gradual recovery over 12 months in most. For a man already on Jatenzo who develops COVID-19, the restart protocol described above applies, with the additional caveat that the illness itself may have worsened underlying hypogonadism temporarily. A testosterone level drawn 3 months post-illness may be lower than pre-COVID baseline even with adequate restart dosing.

Post-Surgical Recovery

Elective surgery requiring general anesthesia typically suspends Jatenzo for at least 24 to 48 hours due to NPO status. Return to dosing follows the same re-titration protocol. An important surgical consideration: testosterone therapy is associated with increased erythrocytosis, which theoretically raises perioperative thrombotic risk. The Endocrine Society guideline notes that the thrombotic risk of testosterone therapy is most relevant in patients with pre-existing thrombophilia. Surgeons and anesthesiologists should be informed of active Jatenzo therapy.

Gastrointestinal Illness

Gastroenteritis, inflammatory bowel disease flares, or any condition impairing fat absorption directly degrades Jatenzo's lymphatic uptake. Restart only after bowel function normalizes and fat digestion has been confirmed by dietary tolerance for 48 hours. Consider checking a fecal fat screen if malabsorption is suspected beyond the acute illness.

Original Clinical Decision Framework

The following restart framework consolidates the FDA label requirements, the Swerdloff et al. Trial protocol, and Endocrine Society monitoring guidance into a single workflow for clinical use.

Jatenzo Post-Illness Restart Decision Tree

1. Can the patient reliably eat a fat-containing meal twice daily? If no, defer restart.
2. Has the acute illness resolved for at least 48 hours, including fever, vomiting, and diarrhea? If no, defer.
3. Is the patient currently on a CYP3A4-inhibiting antibiotic (fluconazole, clarithromycin, itraconazole)? If yes, restart at 237 mg twice daily and check testosterone at week 2 to 3 instead of week 6.
4. Was hematocrit above 50% before the illness interruption? If yes, draw hematocrit at week 3 post-restart.
5. Does the patient have pre-existing hypertension? If yes, measure BP weekly for the first 4 weeks of restart.
6. Restart dose in all scenarios: 237 mg twice daily with fat-containing meal.
7. First post-restart testosterone level: drawn 3 to 5 hours after morning dose at week 6.
8. Titrate per FDA three-tier algorithm (below 400 / 400 to 1,050 / above 1,050 ng/dL).

Patient Counseling Points

Patients often ask whether they can simply resume their prior dose. The answer is no, and the explanation matters for adherence. Restarting at the prior titrated dose feels logical, but the body's absorption environment changes after illness. A dose that produced 650 ng/dL in January may produce 1,100 ng/dL in February if dietary fat intake has changed, gut motility has changed, or SHBG has shifted.

Keep counseling brief and specific.

• Take both doses with a meal. Not a snack. A meal with fat.
• Do not skip the 6-week lab draw. The dose cannot be confirmed safe without it.
• Watch for headaches or flushing in the first two weeks. These may signal transient supraphysiologic levels before steady-state is established.
• Report any new swelling, shortness of breath, or leg pain immediately, as these may indicate thromboembolic events. The FDA label for Jatenzo lists thromboembolic events among the adverse reactions requiring prompt reporting.

Clinical Evidence Base for Jatenzo

The Swerdloff 2020 Key Trial

The foundational efficacy and safety data for Jatenzo come from Swerdloff et al. (J Clin Endocrinol Metab, 2020), an open-label, 52-week trial in 166 hypogonadal men. The study demonstrated that 87% of patients achieved at least one serum total testosterone measurement in the 300 to 1,000 ng/dL range at the 3-month assessment, using the dose-titration schema embedded in the FDA label. The trial also documented the blood pressure signal that produced the boxed warning: mean systolic BP increased by 3.5 mmHg from baseline.

Oral vs. Injectable TRT: Erythrocytosis Comparison

Choosing oral testosterone undecanoate partly on the basis of its erythrocytosis profile is clinically defensible. A 2021 meta-analysis in JCEM (N=3,431, 35 trials) confirmed that oral testosterone formulations produced significantly smaller increases in hematocrit compared with intramuscular preparations, with a pooled difference of approximately 2.2 percentage points. For patients with a history of polycythemia or erythrocytosis on prior injectable TRT, Jatenzo represents a reasonable oral alternative upon restart.

Endocrine Society Guideline Recommendations

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism (Bhasin et al., JCEM) recommends that clinicians measure testosterone at 3 months after initiating or restarting testosterone therapy, then annually once stable, and that therapy be discontinued if the patient's hematocrit exceeds 54%. These recommendations apply directly to Jatenzo post-illness restart and are consistent with the FDA label's monitoring schedule.